Webinar: Bispecific Antibody-Drug Conjugates (BsADCs): An Emerging, Promising Anti-Cancer Therapeutic Modality With Improved Efficacy And Safety
Our webinar “Bispecific Antibody-Drug Conjugates (BsADCs): An Emerging, Promising Anti-Cancer Therapeutic Modality With Improved Efficacy And Safety” was live at 12:00 PM EDT on July 19th, 2023.
About the Webinar
Bispecific ADCs (BsADCs) are emerging as a promising modality in anti-cancer therapies. BsADCs offer increased target diversity and selectivity from the dual targeting antibody moiety, in combination with the targeted delivery of cytotoxic payloads for potent tumor cell killing. In this webinar, Dr. W. Frank An will outline the current progress in the BsADC field and highlight Biocytogen’s ongoing BsADC programs.
W. Frank An, PhD.
Sr. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals
Vivian Tian, PhD.
Sr. Director, Business Development & Licensing, Biocytogen European Innovation Center, Biocytogen Pharmaceuticals
Jenna Frame, PhD
Sr. Manager, Scientific Communications & Marketing, Biocytogen Boston